Maybe I have misunderstood, I thought this trial, phase 1, was to test the safety aspects of Recce 327 on healthy subjects, prior to phase 2 trials where they test the safety and efficacy against sepsis, etc. In this trial there will not be any sepsis present. So if that is correct then they could test infusion, nasal and oral pathways. It would seem like overkill if they had to do repeat phase 1 trials for R 327 for each pathway imo..
RCE Price at posting:
$1.48 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)